1952 — Everest Medicines Share Price
0.000.00%
Last trade - 00:00- HK$14.57bn
- HK$13.48bn
- CNY706.68m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.57 | ||
| Price to Tang. Book | 8 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 20.58 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -26.82% | ||
| Return on Equity | -23.04% | ||
| Operating Margin | -158.07% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | n/a | 0.05 | 12.79 | 125.93 | 706.68 | 1,498.5 | 2,341 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Everest Medicines Ltd is a biopharmaceutical company primarily engaged in the discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines. The Company has built a product pipeline across renal, anti-infective, and autoimmune diseases. The Company’s products portfolio includes Nefecon (TARPEYO) using in the renal therapeutic area, XERAVA (eravacycline) using in the treatment of infections caused by susceptible gram-positive, gram-negative and anaerobic pathogens including those multidrug resistant isolates and other products. The Company conducts its business in the domestic and overseas markets.
Directors
- Wei Fu CHM (38)
- Ian Woo PRE (48)
- Kerry Blanchard CEO (65)
- Xiaofan Zhang COO (37)
- Xinhui Hu CTO (47)
- Jason Brown OTH (49)
- Kevin Guo OTH (51)
- Yang Shi OTH (45)
- Jennifer Yang OTH
- Xu Zhu OTH (50)
- Zhengying Zhu OTH (48)
- Yee Wa Lau SEC (48)
- Yubo Gong NED (35)
- Lan Kang NED (52)
- Shidong Jiang NID (53)
- Yifan Li NID (53)
- Bo Tan NID (47)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 1st, 2017
- Public Since
- October 9th, 2020
- No. of Employees
- 665
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 326,662,307
- Address
- 16/F., CITIC Pacific Plaza,, SHANGHAI, 200041
- Web
- https://www.everestmedicines.com/
- Phone
- Auditors
- PricewaterhouseCoopers
Upcoming Events for 1952
Half Year 2025 Everest Medicines Ltd Earnings Release
Similar to 1952
3D Medicines
Stock Exchange of Hong Kong Limited
3SBio
Stock Exchange of Hong Kong Limited
AIM Vaccine Co
Stock Exchange of Hong Kong Limited
Ascletis Pharma
Stock Exchange of Hong Kong Limited
Asymchem Laboratories Tianjin Co
Stock Exchange of Hong Kong Limited
FAQ
What is the Everest Medicines share price?
As of Today at 20:32 UTC, shares in Everest Medicines are trading at HK$47.40. This share price information is delayed by 15 minutes.
How has the Everest Medicines share price performed this year?
Shares in Everest Medicines last closed at HK$47.40 and the price had moved by +96.68% over the past 365 days. In terms of relative price strength the Everest Medicines share price has outperformed the FTSE Developed Asia Pacific Index by +98.93% over the past year.
What are the analyst and broker recommendations for Everest Medicines?
The overall consensus recommendation for Everest Medicines is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Everest Medicines dividend yield?
Everest Medicines does not currently pay a dividend.
Does Everest Medicines pay a dividend?
Everest Medicines does not currently pay a dividend.
When does Everest Medicines next pay dividends?
Everest Medicines does not currently pay a dividend.
How do I buy Everest Medicines shares?
To buy shares in Everest Medicines you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Everest Medicines?
As of the previous close price of HK$47.40, shares in Everest Medicines had a market capitalisation of HK$14.57bn.
Where are Everest Medicines shares listed?
Here are the trading details for Everest Medicines:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 1952
What kind of share is Everest Medicines?
Based on an overall assessment of its quality, value and momentum Everest Medicines is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Everest Medicines share price forecast for 2025?
The analyst consensus target price for shares in Everest Medicines is HK$55.08. That is 16.2% above the last closing price of HK$47.40.
Analysts covering Everest Medicines currently have a consensus Earnings Per Share (EPS) forecast of -CNY0.95 for the next financial year.
Find out moreWhat is the trend in the Everest Medicines share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Everest Medicines. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +46.86%.
As of the last closing price of HK$47.40, shares in Everest Medicines were trading +32.01% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Everest Medicines PE Ratio?
The Everest Medicines PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$47.40.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Everest Medicines?
Everest Medicines' management team is headed by:
- Wei Fu - CHM
- Ian Woo - PRE
- Kerry Blanchard - CEO
- Xiaofan Zhang - COO
- Xinhui Hu - CTO
- Jason Brown - OTH
- Kevin Guo - OTH
- Yang Shi - OTH
- Jennifer Yang - OTH
- Xu Zhu - OTH
- Zhengying Zhu - OTH
- Yee Wa Lau - SEC
- Yubo Gong - NED
- Lan Kang - NED
- Shidong Jiang - NID
- Yifan Li - NID
- Bo Tan - NID